A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Efavirenz, Lamivudine and Tenofovir Disoproxil (SYMFI)

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class · 1 generic manufacturer · 2 ANDAs filed at FDA.

First FDA approval2018-04-25
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Efavirenz, Lamivudine and Tenofovir Disoproxil used for?

Efavirenz, Lamivudine and Tenofovir Disoproxil is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Efavirenz, Lamivudine and Tenofovir Disoproxil?

Yes. 2 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Efavirenz, Lamivudine and Tenofovir Disoproxil?

NADAC pricing data not currently available for this drug.

Is Efavirenz, Lamivudine and Tenofovir Disoproxil on the FDA shortage list?

No. Efavirenz, Lamivudine and Tenofovir Disoproxil is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor6 alternatives in D1
01
Doravirine
Brand: PIFELTRO
$60.95Lowest NADAC
0Generic mfrs
$121.3MCY24 Part D spend
Compare →
02
Doravirine, Lamivudine, and Tenofovir Disoproxil
Brand: DELSTRIGO
$92.91Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Efavirenz
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
$1.37Lowest NADAC
5Generic mfrs
$5.8MCY24 Part D spend
Compare →
04
Efavirenz, Emtricitabine and Tenofovir Disoproxil
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
$1.31Lowest NADAC
6Generic mfrs
CY24 Part D spend
Compare →
05
Etravirine
Brand: Intelence
$7.77Lowest NADAC
3Generic mfrs
$35.4MCY24 Part D spend
Compare →
06
Nevirapine
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
$0.144Lowest NADAC
7Generic mfrs
$2.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.